Topic
Clinical Trials
76 Podcasts • 14 Cases • 10 Courses on BackTable
Episode # 75 • 04 Aug 2026
Applying CheckMate 8HW: Practical Updates for MSI-High CRC
with Dr. Cathy Eng, Dr. Jun Gong
Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical oncologist Jun Gong interviews Dr. Cathy Eng about updates from the phase III CheckMate-8HW trial in centrally confirmed MSI-high/dMMR metastatic colorectal cancer, comparing nivolumab/ipilimumab, nivolumab, and chemotherapy. They discuss initial findings demonstrating improved progression-free survival and response rates with combination immunotherapy, as well as safety considerations and how comorbidities and frailty guide the choice between single-agent and combination regimens.
This podcast is supported by
More on Clinical Trials
Loading recent podcasts…
Tumor Board # 75
Aug 4, 2026
with Dr. Cathy Eng, Dr. Jun Gong
Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor...
110+ listens
Urology # 316
Jul 14, 2026
with Dr. Adam Gadzinski, Dr. Ruchika Talwar
As bladder cancer treatment options expand, so do the challenges of delivering them in real-world practice. On this...
850+ listens
Urology # 314
Jul 7, 2026
with Dr. Rana McKay, Dr. Emmanuel Antonarakis, Dr. Alan Tan
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for...
900+ listens
Urology # 311
Jun 23, 2026
with Dr. Pat Keegan, Dr. Kelly Parsons, Dr. Raj Pruthi
What happens when urologists look beyond the clinic and take on leadership in the life sciences industry? In this...
910+ listens
Tumor Board # 74
Jul 28, 2026
with Dr. Chih-Yi Liao, Dr. Robert Ramirez, Dr. Lingling Du
What first-line therapies should be considered for patients with higher-grade, metastatic neuroendocrine tumors (NETs)?...
110+ listens
Tumor Board # 71
Jul 7, 2026
with Dr. Rana McKay, Dr. Emmanuel Antonarakis, Dr. Alan Tan
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for...
160+ listens
Vascular & IR # 659
Jun 30, 2026
with Dr. Beau Toskich, Dr. Lingling Du, Dr. Tyler Sandow
How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional...
1,200+ listens
Tumor Board # 68
Jun 23, 2026
with Dr. Dawood Findakly, Dr. Gregory Botta
Can the latest therapies, lessons from clinical trials, and a focus on emotional support improve outcomes for patients...
310+ listens
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
Tumor Board Case
Oct 28, 2025
with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
VI Case
Jun 16, 2026
with Dr. Tyler Sandow, Dr. Beau Toskich, Dr. Christopher Malone and Dr. Zach Berman
Tumor Board Case
Oct 28, 2025
with Dr. Dylan Roden, Dr. Ravindra Uppaluri and Dr. Adam Luginbuhl
Tumor Board Course
2 CME/CE credits, 2.5 hours, 19 lessons
Urology Course
3 hours, 28 lessons
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.